Ask AI to review this stock
Copy the prompt to get recent events, historical reactions, and a short research brief.
Tell your AI:
Help me set up FinLab and analyze 6242 立康. Please read: https://finlab.finance/en/setup?stock=6242
6242
steady quality, fair valuation, no active signal today.
Is 立康 a buy? Fundamentals and valuation first
-
Above-average profitability.Operating margin is in the 64th market percentile. Latest quarterly ROE ≈ 1.2%.
-
Valuation is neutral.PE is in the 26th market percentile; within its own history, PE is around the 58th percentile.
Chip flow
Institutional rotation, concentration steady — bullish
Window from 2026-01-17 · Price -6% · branches to 2026-06-17· TDCC to 2026-06-12
- Largest holder 元大-沙鹿 has accumulated 53 lots since the start (sold 0%), still adding.
- Main distributor 日茂-埔里 peaked at 26 lots, has sold 38%, 16 left, paused recently.
- TDCC big holders (absolute) >1000-lot holders +0.00pp, mid holders +0, retail -0.03pp — little change.
- Foreign hedge-desk net short Net short -2 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Accumulating
- 元大-沙鹿 +53
- 玉山證券 +26
- 富邦-公益 +22
- 國泰-館前 +22
- 凱基-永康 +19
- 永豐金-永康 +18
Distributing
- 日茂-埔里 16 left
- 元大-林森 7 left
- 台新-高雄 8 left
- 國泰-敦南 2 left
- 元大-上新莊 3 left
- 富邦-嘉義 3 left
Desks
- 玉山-城中 -58
- 第一金-路竹 -28
- 元大-忠孝鼎富 -22
- 元大-大灣 -21
Mixed direction: big-holder and retail changes are not aligned.
Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.
Historical evidence
Valuation regime and subsequent returns
Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.
| PE percentile band | Sample days | 240-day avg return | Median | Win rate | Avg excess (vs index) |
|---|---|---|---|---|---|
| 0-20 | 231 | +10.7% | +1.2% | 51.1% | -13.9% |
| 20-40 | 482 | -2.6% | -4.6% | 29.5% | -23.9% |
| 40-60 You are here | 412 | +18% | +12.8% | 72.6% | -1.4% |
| 60-80 | 399 | +5.2% | -2.8% | 38.1% | -23.9% |
| 80-100 | 116 | +27.5% | +39.6% | 75% | +7% |
Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.
Current PE ≈ 15.04, at the 57.6th percentile of its own history (40-60 band).
Valuation × momentum historical grid
Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.
Currently in “Mid × 60-day momentum up”: across 455 historical days, 120-day forward avg gained 4%, win rate 42.4%, lagged the market by 8.4%.
Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.
Signals not active (historical stats for reference)
These are not occurring now; historical samples shown for comparison.
252-day price high (breakout)
PendingAdjusted close makes a new 252-day high; repeats within 20 days counted once.
8 times historically; 60-day forward avg -0.51%, win rate 62.5%, beating the market by -2.6 pts on average.
Monthly revenue YoY ≥ 20% (from filing deadline)
PendingMonthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).
77 times historically; 60-day forward avg -2.77%, win rate 47.5%, beating the market by -5.27 pts on average.
Foreign net buying for 5 straight days
PendingForeign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.
7 times historically; 60-day forward avg +2.81%, win rate 71.4%, beating the market by -1.9 pts on average.
What does 立康 do? Company profile
Overview
6242 對應立康生醫事業股份有限公司，為櫃買中心上櫃普通股，非 ETF、ETN、特別股或權證。公司成立於 1985-04-16，公開發行日為 1999-07-16，興櫃日為 2002-06-18，上櫃日為 2003-04-23；總部位於台南市永康區王行里環工路 29 號。董事長與總經理皆為鄭育修，發言人為莊祐霖。實收資本額約新台幣 3.18 億元，已發行普通股 31,806,500 股，無特別股。2026 年股東會年報揭露，115 年 4 月 30 日止員工 145 人，平均年齡 42.4 歲、平均服務年資 5.8 年。法人董事與主要關係股東包含宏育投資股份有限公司、立康生物科技股份有限公司；年報揭露立康生物科技股份有限公司之主要股東包含鄭育修、生春堂製藥工業股份有限公司、鄭智文、黃雅翌、美康投資、尚毅投資、益邦投資、南友投資、宏育投資及吳碧容等。公司前身為亨豐科技，2014 年經營團隊接手後轉型為以觀光工廠、電話行銷及保健食品、藥品銷售為主的生醫通路公司。
Business
立康的核心模式是以觀光工廠結合中草藥、生技保健與專業健康諮詢，銷售藥品、保健食品、食品、美容清潔商品、醫療器材與棉織品等；同時提供電話行銷、產品宅配、售後服務、會員回購與網路訂購。公司目前主要營運據點包括台南「立康中草藥產業文化館」與苗栗「立康健康養生觀光工廠」，兩者皆取得經濟部觀光工廠認證；南投埔里第三座觀光工廠已動土興建，定位為較大型、結合周邊觀光資源與自由行散客的新據點。2025 年（民國 114 年）合併營收新台幣 589,209 仟元、年增 4.19%，稅後淨利 83,824 仟元、年增 8.83%；銷售地區為內銷 100%。營收增加主因為客購營業額、實體觀光工廠營業額及子公司營業額增加。公司揭露單一客戶銷售金額均未占銷貨總額 10% 以上，最終客戶為不特定一般消費者，以及中醫診所、醫療院所、藥品經銷商等。產品多以外購商品為主，主要供應來自立康生物科技、生春堂製藥及其他保密代號供應商；公司本身不以研發製造為主，未配置專職研發人員，新品多由企劃部門依市場調查與保健養生趨勢規劃。早期公開資料曾指出保健食品為最大營收來源、其次為藥品；較近期年報未完整揭露產品別營收占比，因此目前僅能確認內銷占比與主要銷售型態。
Outlook 2025–2028
2025 年已見營收與獲利小幅成長，觀光工廠來客回升、客購會員業務、官網與電銷回購為主要支撐。2026 年公司經營方針包括增設營業據點、持續推出新產品、拉高客單價、推動客購行銷管理、利用會員資料庫做精準銷售、建構跨業種旅遊平台，以及擴展網路購物平台。南投埔里觀光工廠為中期最大成長動能之一；該案位於埔里酒廠旁，土地面積約 4,925 坪，2024 年動土，2025 年公告機電工程發包金額新台幣 1.3 億元，媒體報導公司預期可能耗時 2 至 2.5 年，最快 2026 年開業。若順利開幕，2026-2028 年可望擴大中部據點、提高散客占比、降低過往對團客的依賴，並與南投在地觀光資源合作。產業面，台灣觀光工廠產值近年約 66-67 億元、進入成熟期，成長重點將由單純來客數轉向客單價、體驗價值、智慧觀光與跨域合作；保健食品市場則受高齡化、健康意識、女性與年輕族群日常保健需求、電商與社群導購帶動。主要風險包括國旅需求受出國潮排擠、觀光工廠競爭激烈、遊覽車與團客動線變化、保健食品同質化與法規限制、產品來源高度依賴關係人及少數供應商、南投新廠建設期程與投資回收不確定、以及公司董事長兼任總經理造成治理上需持續依賴獨立董事監督。
Supply Chain
- 立康生物科技股份有限公司 未上市關係企業，年報列為主要供應商，供應藥品、保健食品及醫療器材等；2025 年進貨占比 52.74%，2026 年第一季占比 56.47%。
- 生春堂製藥工業股份有限公司 未上市關係企業，為中草藥及保健食品等專業製造廠商；年報說明立康目前仍以購入立康生技及生春堂生產產品為銷售主軸。
- A 公司 非關係人供應商，因營業保密約定以代號揭露；2025 年進貨占比 18.85%，2026 年第一季占比 16.73%。
- 國內廠商及代理商 供應藥品、保健食品、食品、美容清潔商品、醫療器材等外購商品；年報稱供應來源以國內廠商及代理商為主，供應不虞匱乏，部分供應商以 B、C、D、E、F 公司代號揭露。
- 台灣糖業股份有限公司 未上市國營事業；立康 2023 年與台糖簽訂南投埔里土地租賃合約，作為第三座觀光工廠基地。
- 銓興營造有限公司 非關係人、未上市；2025 年公告為南投埔里觀光工廠機電工程契約相對人，契約金額新台幣 1.3 億元。
- 一般消費者與會員客戶 觀光工廠、電話行銷、網路訂購及宅配的主要終端客群；公司推動會員資料庫與客購行銷以提高回購率與忠誠度。
- 中醫診所、醫療院所及藥品經銷商 年報列示之銷售與服務對象，單一客戶未占銷貨總額 10% 以上。
- 旅行社、遊覽車業者、餐飲、旅館與民宿業者 觀光工廠導客與跨業種旅遊平台合作對象；多為非上市櫃或未揭露特定公司名稱。
- 學校、家庭旅遊與銀髮族團體 觀光工廠體驗、DIY 活動、用藥安全宣導與健康講座的目標客群；非公司型客戶。
Competitors
Sources（15）
This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.
Method and limitations
- All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
- Excess return is measured against the TAIEX total-return index (dividends included).
- Valuation regime and percentile stats use an expanding own-history window (no future data).
- Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
- Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.
This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.